Abstracts tagged "medication"

Abstract Number: 135 • 2023 Pediatric Rheumatology Symposium
Assessing Medication Adherence in JIA: Pilot Phase Results from a Single-Center Quality Improvement Initiative
Dori Abel¹, Joyce Chang², Jon Burnham³, Chen Kenyon⁴ and Sabrina Gmuca⁵, ¹Department of Pediatrics, Division of Rheumatology, Children’s Hospital of Philadelphia; PolicyLab, Children's Hospital of Philadelphia, Philadelphia, PA, ²Boston Children's Hospital, Boston, MA, ³Department of Pediatrics, Division of Rheumatology, Children’s Hospital of Philadelphia; Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁴Department of Pediatrics, University of Pennsylvania Perelman School of Medicine; PolicyLab, Children’s Hospital of Philadelphia, Philadelphia, PA; Leonard Davis Institute of Health Economics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁵Department of Pediatrics, Division of Rheumatology, Children’s Hospital of Philadelphia; Center for Pediatric Clinical Effectiveness, Children’s Hospital of Philadelphia; PolicyLab, Children's Hospital of Philadelphia; Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
Background/Purpose: Suboptimal medication adherence is a widespread problem in JIA. There are several unique features to medication adherence in JIA, including that the medications used…
Abstract Number: 092 • 2020 Pediatric Rheumatology Symposium
The Initial Treatment of Systemic Juvenile Idiopathic Arthritis: An International Collaboration Among 10 Registries
Mary Beth Son¹, Yukiko Kimura ², Kristiina Aalto ³, Lillemor Berntson ⁴, Johnathan Dallas ¹, Ciaran Duffy ⁵, Mia Glerup ⁶, Jaime Guzman ⁷, Troels Herlin ⁸, Petteri Hovi ⁹, Kimme Hyrich ¹⁰, Jens Klotsche ¹¹, Bo Magnusson ¹², Vanessa McIntyre ¹³, Ellen Nordal ¹⁴, Seza Ozen ¹⁵, Maria Jose Santos ¹⁶, Betul Sozeri ¹⁷ and Timothy Beukelman ¹⁸, ¹Boston Children's Hospital, Boston, Massachusetts, ²Hackensack Meridian School of Medicine, Hackensack, ³Department of Pediatrics, New Children's Hospital, Helsinki University Hospital, Pediatric Research Center, University of Helsinki, Helsinki, Finland., HUS, Finland, ⁴Department of Womens and Childrens Health, Uppsala University, Uppsala, Sweden., Uppsala, Sweden, ⁵Ottawa, Canada, ⁶Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, Aarhus, Denmark, ⁷University of British Columbia and BC Children's Hospital, Vancouver, Canada, ⁸Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark., Aarhus N, Denmark, ⁹Helsinki University Hospital, Helsinki, Finland, ¹⁰Manchester, United Kingdom, ¹¹Berlin, Germany, ¹²Karolinska University Hospital, Stockholm, Sweden, ¹³Manchester University, Manchester UK, United Kingdom, ¹⁴Department of Pediatrics, University Hospital of North Norway, and Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway., Tromsø, Norway, ¹⁵Hacettepe University, Division of Pediatric Rheumatology, Department of Pediatrics, Faculty of Medicine, ¹⁶Portugal, ¹⁷Boston, Turkey, ¹⁸University of Alabama at Birmingham, Birmingham
Background/Purpose: The introduction of biologic medications has revolutionized the care of children with systemic juvenile idiopathic arthritis (SJIA). Differences in treatment approaches among different countries…
Abstract Number: 096 • 2020 Pediatric Rheumatology Symposium
Medication Adherence in Adolescents and Young Adults with Childhood Onset SLE
Rotem Semo Oz¹, Linda Wagner-Weiner ², Cuoghi Edens ¹, Grace Cameron ¹ and Melissa Tesher ¹, ¹university of chicago, Chicago, ²University of Chicago, Chicago, Illinois
Background/Purpose: Compared to adults with SLE, young patients with SLE face particular challenges, including more severe disease, more renal involvement and medications side effects like…
Abstract Number: 127 • 2020 Pediatric Rheumatology Symposium
Disease Characteristics and Medication Utilization in Lupus Nephritis Associated with Childhood-Onset Systemic Lupus Erythematosus
Emily Smitherman¹, Rouba Chahine ¹, Timothy Beukelman ¹, Laura Lewandowski ², AKM Fazlur Rahman ¹, Scott Wenderfer ³, Aimee Hersh ⁴ and Jeffrey R Curtis ⁵ for the CARRA investigators, ¹University of Alabama at Birmingham, Birmingham, ²NIAMS, NIH, Rockville, ³Section of Nephrology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, ⁴University of Utah Primary Children's Hospital, Salt Lake City, ⁵University of Alabama at Birmingham, Hoover
Background/Purpose: Lupus nephritis associated with childhood-onset systemic lupus erythematosus (cSLE) is a significant risk factor for long-term morbidity and mortality, but little is known regarding…
Abstract Number: 271 • 2019 ACR/ARP Annual Meeting
Who Prescribed Which Osteoporosis Medication to Whom
Jiannong Liu¹, Haifebg Guo ¹, Tingting Gong ¹ and Yi Peng ², ¹Hennepin Healthcare Research Institute, Minneapolis, MN, ²Chronic Disease Research Group, Hennepin Healthcare Research Institute, Minneapolis, MN
Background/Purpose: Several osteoporosis (OP) medicines came on the market in the past two decades, each with its own indications. However, there is no clear information…
Abstract Number: 2202 • 2019 ACR/ARP Annual Meeting
Trends in Prescribing of NSAIDs and Opioids Among Osteoarthritis Patients in British Columbia, Canada, 1998-2014
Jacek Kopec¹, Jolanda Cibere ², Na Lu ³, Hui Xie ⁴, J. Antonio Avina-Zubieta ¹ and John Esdaile ⁵, ¹Arthritis Research Canada and the University of British Columbia, Vancouver, BC, Canada, ²Arthritis Research Canada and the University of British Columbia, Vancouver, Canada, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴Arthritis Research Canada and Simon Fraser University, Vancouver, BC, Canada, ⁵Arthritis Research Canada and the University of British Columbia, Richmond, BC, Canada
Background/Purpose: Non-steroidal anti-inflammatory drugs (NSAIDs) and opioids are commonly prescribed for patients with osteoarthritis (OA). However, both types of medication are associated with serious side…
Abstract Number: 2203 • 2019 ACR/ARP Annual Meeting
Impact of Hypothetical Changes in the Use of Analgesics on the Burden of Osteoarthritis: A Population-based Microsimulation Study
Jacek Kopec¹, Eric Sayre ², Anya Okhmatovskaia ³, Jolanda Cibere ⁴, Linda Li ⁵, Nick Bansback ⁶, Hubert Wong ⁵ and John Esdaile ⁷, ¹Arthritis Research Canada and the University of British Columbia, Vancouver, BC, Canada, ²Arthritis Research Canada, Vancouver, BC, Canada, ³McGill University, Montreal, QC, Canada, ⁴Arthritis Research Canada and the University of British Columbia, Vancouver, Canada, ⁵University of British Columbia, Vancouver, BC, Canada, ⁶University of British Columbia, Vancouver, Canada, ⁷Arthritis Research Canada and the University of British Columbia, Richmond, BC, Canada
Background/Purpose: Analgesics are the cornerstone of medical treatment of osteoarthritis (OA) but are associated with serious side effects. A more optimal use of analgesics in…
Abstract Number: 2764 • 2019 ACR/ARP Annual Meeting
Medication Necessity and Concerns Beliefs Are Distinct, Interactive Predictors of Treatment Adherence in Rheumatoid Arthritis
George Karpouzas¹, Elizabeth Hernandez ², Lorena Ruiz ³, Vibeke Strand ⁴ and Sarah Ormseth ¹, ¹Harbor-UCLA Medical Center and Los Angeles Biomedical Institute, Torrance, CA, ²Harbor-UCLA and Los Angeles Biomedical Institute, Torrance, CA, ³Harbor-UCLA andLos Angeles Biomedical Research Institute, Torrance, ⁴Division of Immunology/Rheumatology, Stanford University, Stanford, CA
Background/Purpose: Medication adherence is instrumental for the successful management of rheumatoid arthritis (RA) to a goal of remission. Awareness of medication necessity and concerns regarding…
Abstract Number: 460 • 2018 ACR/ARHP Annual Meeting
Immunomodulatory Medication Use for Youth with Newly-Diagnosed Systemic Lupus Erythematosus
Alaina M. Davis¹, Marisa S. Klein-Gitelman², Jennifer Faerber³, Hannah Katcoff⁴, Zuleyha Cidav⁵, David Mandell⁶ and Andrea M. Knight⁷, ¹Division of Pediatric Rheumatology, Monroe Carell Junior Children's Hospital at Vanderbilt, Nashville, TN, ²Division of Pediatric Rheumatology/PDD PTD, Lurie Children's Hospital of Chicago/Northwestern University, Chicago, IL, ³Division of General Pediatrics, Center for Pediatric Clinical Effectiveness, The Children’s Hospital of Philadelphia, Philadelphia, PA, ⁴Center for Pediatric Clinical Effectiveness, The Children’s Hospital of Philadelphia, Philadelphia, PA, ⁵Perelman School of Medicine, Center for Mental Health Policy and Services Research, University of Pennsylvania, Philadelphia, PA, ⁶Psychiatry and Pediatrics, Center for Mental Health Policy and Services Research, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁷Division of Rheumatology, Center for Pediatric Clinical Effectiveness & PolicyLab, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: To examine immunomodulatory medication use for youth with systemic lupus erythematosus (SLE) during their first year of care. Methods: We conducted a retrospective cohort…
Abstract Number: 1263 • 2018 ACR/ARHP Annual Meeting
Develop a Master Algorithm for Drug Withdraw Strategy in Reduction of Adverse Events – a Machine Learning Model from the Smart System of Disease Management (SSDM)
Yan Zhao¹, Jing Yang², Jianlin Huang³, Hua Wei⁴, Yongfu Wang⁵, Rong Mu⁶, Xiaoxia Zuo⁷, Hongzhi Wang⁸, Xinwang Duan⁹, Jing Xue¹⁰, Hongsheng Sun¹¹, Bin Wu¹², Lirong Kang⁵, Feng Wei¹³, Cundong Mi¹⁴, Yanping Zhao¹⁵, Yang Li¹⁶, Haiying Chen¹⁷, Zhenbin Li¹⁸, Qingliang Meng¹⁹, Yuhua Jia²⁰, Hui Xiao²⁰ and Fei Xiao²⁰, ¹Rheumatology, Peking Union Medical College Hospital, Beijing, China, ²Department of rheumatology, Central Hospital of MianYang, Sichuan, Mian Yang, China, ³Department of rheumatology, The Sixth Hospital Affiliated to Sun yat-sen University, Guangzhou, China, ⁴Northern Jiangsu People's Hospital, Yangzhou, China, ⁵The First Affiliated Hospital of BaoTou Medical College, Baotou, China, ⁶Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ⁷Xiangya Hospital Central South University, Changsha, China, ⁸The First Hospital of Jiaxing, Jiaxing, China, ⁹Department of rheumatology, The Second Affiliated Hospital of Nanchang University, Nanchang, China, ¹⁰88 Jiefang Road, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China, ¹¹Department of Rheumatology and Immunology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China, ¹²Department of Rheumatology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, China, ¹³JIANGMEN CENTRAL HOSPITAL, AFFILIATED JIANGMEN HOSPITAL OF SUN YAT-SEN UNIVERSITY, Jiangmen, China, ¹⁴The Second Affiliated Hospital of Guangxi Medical University, Nanning, China, ¹⁵The First Affiliated Hospital of Harbin Medical University, Harbin, China, ¹⁶The Second Affiliated Hospital of Harbin Medical University, Harbin, China, ¹⁷The third hospital of hebei medical university, Shijiazhuang, China, ¹⁸Peace Hospital, Shijiazhuang, China, ¹⁹Henan Province Hospital of TCM, Zhengzhou, China, ²⁰Shanghai Gothic Internet Technology Co., Ltd., Shanghai, China
Background/Purpose: Combination therapy with DMARDs for treating RA is considered as standard of care. However, certain rates of adverse events (AEs) are unavoidable. The stigma…
Abstract Number: 2194 • 2017 ACR/ARHP Annual Meeting
The Relationship between the Number of Prescription Medications and Physical Activity Amongst Patients with or at High Risk for Knee Osteoarthritis
Nivaas Thanoo¹, Abigail Gilbert², Jing Song³, Dorothy D. Dunlop⁴ and Rowland W. Chang⁵, ¹Feinberg School of Medicine, Chicago, IL, ²Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Center for Healthcare Studies, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Inst Hlthcare Studies, Northwestern Univ/ Feinberg, Chicago, IL, ⁵Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Physical activity amongst individuals with knee osteoarthritis (KOA) has been linked to improved pain, functional status, and less disability. It is important to understand…
Abstract Number: 2820 • 2017 ACR/ARHP Annual Meeting
Disease Activity By the Sledai in Lupus Patients Who Self Report Sleep Disturbance and Sleep Impairment Using the Patient-Reported Outcomes Measurement Information System Instruments
Teresa Aberle¹, Rufei Lu², Sarah Cioli³, Stan Kamp¹, Wade DeJager¹, Stephen Apel⁴, Cristina Arriens⁵, Eliza Chakravarty⁶, Aikaterini Thanou¹, Joel M. Guthridge⁷, Joan T. Merrill⁸ and Judith A. James⁹, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Oklahoma Medical research af, Edmond, OK, ⁷Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, OKC, OK, ⁸Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁹Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Lupus patients commonly report sleep dysfunction, which is associated with upregulation of inflammatory cytokines in healthy people. Studies exploring relationships between self-reported sleep dysfunction…
Abstract Number: 1536 • 2017 ACR/ARHP Annual Meeting
Patient Preferences in Medication for Treatment of Spondyloarthritis: A Qualitative Study
Maureen Dubreuil¹, Christian Frese², Shing Law³, Liana Fraenkel⁴, Elena Losina⁵ and Tuhina Neogi⁶, ¹Clinical Epidemiology, Boston University School of Medicine, Boston, MA, ²Boston University School of Medicine, Boston, MA, ³Rheumatology, Boston Medical Center, Boston, MA, ⁴Rheumatology, Rheumatology, Yale University School of Medicine, New Haven, CT, New Haven, CT, ⁵Orthopaedic and Arthritis Center for Outcomes Research, Department of Orthopedic Surgery, Brigham & Women's Hospital, Boston, MA, ⁶Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Medications used in the treatment of spondyloarthritis (SpA) include nonsteroidal anti-inflammatory drugs (NSAIDs) and biologics, with each class having distinct characteristics that patients may…
Abstract Number: 52 • 2017 Pediatric Rheumatology Symposium
How Young People with Juvenile Idiopathic Arthritis and Their Caregivers Weigh the Risks of the Disease and its Treatment: A Mixed-Methods Study
Daniel B. Horton^1,2, Jomaira Salas³, Aleksandra Wec⁴, Timothy Beukelman^5,6, Alexis Boneparth¹, Ky Haverkamp⁷, Melanie Kohlheim⁸, Melissa Mannion⁵, Nandini Moorthy¹, Sarah Ringold⁹ and Marsha Rosenthal², ¹Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ²Rutgers Institute for Health, Health Care Policy and Aging Research, New Brunswick, NJ, ³Department of Sociology, Rutgers, the State University of New Jersey, New Brunswick, NJ, ⁴Rutgers, the State University of New Jersey, New Brunswick, NJ, ⁵Pediatrics, University of Alabama at Birmingham, Birmingham, AL, ⁶Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁷Family Medicine, University of Washington School of Medicine, Seattle, WA, ⁸Pediatric Rheumatology Care and Outcomes Improvement Network, Cincinnati, OH, ⁹Seattle Children's Hospital, Seattle, WA
Background/Purpose: Prior research has examined factors important to clinicians in deciding whether to withdraw therapy for inactive JIA, but little is known about the perspectives…
Abstract Number: 23 • 2017 Pediatric Rheumatology Symposium
Impact of an Institutional Specialty Pharmacy on Adherence to Biologic Therapies
Kelly Wise¹, Dustin Lewis², Bethanne Thomas², Karla Jones³, Stephanie Lemle², Darby MacDonald², Fatima Barbar-Smiley², Vidya Sivaraman² and Cagri Yildirim-Toruner³, ¹Pharmacy/Rheumatology, Nationwide Children's Hospital, Columbus, OH, ²Nationwide Children's Hospital, Columbus, OH, ³Rheumatology, Nationwide Children's Hospital, Columbus, OH
Background/Purpose: Biologic therapies have become a standard of care for many pediatric rheumatic diseases such as juvenile idiopathic arthritis (JIA) and periodic fever syndromes. Biologics,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].